One in Five New Dermatology Drugs Were First in Class Over the Past Decade

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

FRIDAY, Dec. 22, 2023 -- From 2012 to 2022, innovative dermatologic drug development increased, according to a research letter published online Dec. 20 in JAMA Dermatology.

Samir Kamat, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues characterized the frequency and degree of innovation of new dermatologic drugs (topical or systemic) approved by the U.S. Food and Drug Administration from 2012 to 2022.

The researchers identified 52 new drug applications and 26 supplemental new indications approved by the FDA. Among the new drugs, 21 percent were categorized as first in class and 25 percent as first in indication. Health technology assessment organizations in Germany, Canada, or France rated 39 percent of new drugs as clinically useful or having high added therapeutic benefit and 30 percent of the supplemental new indications as clinically useful or having high added therapeutic benefit.

"This study suggests that innovative dermatologic drug development may have increased over the past decade, offering promise for patients with skin disease," the authors write. "However, these findings also highlight opportunities to develop more truly innovative dermatologic agents, particularly for diseases with unmet therapeutic need."

Several authors disclosed ties to industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-23 06:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords